Cranberry fruit in COVID-19

Comparison of the effectiveness of cranberry fruit and placebo in the treatment of symptoms of Covid-19 patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101201005287N3

Enrollment

120

Registered

2022-02-22

Start date

2021-12-09

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, virus identified. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: For 14 days, patients received the cranberry capsule (500 g) prepared in Tabriz School of Pharmacy, while receiving it from the researcher while visiting Imam Reza

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Confirmation of Covid-19 by PCR test Satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Having an underlying disease Pregnant patients Stop taking the drug

Design outcomes

Primary

Measure	Time frame
Interleukin-6 blood levels of patients before and after taking the drug. Timepoint: Before starting the drug and 14 days after taking the drug. Method of measurement: Blood sample analysis for IL-6 by ELISA in the laboratory.	—

Secondary

Measure	Time frame
Serum TNF-a levels in patients' plasma. Timepoint: At the beginning of the study (before the intervention) and 14 days after starting the drug. Method of measurement: Blood sample analysis for TNF-a by ELISA in the laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkbar Sharifi

Tabriz University of Medical Sciences

asharifi@tbzmed.ac.ir+98 41 1337 5449

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026